• Explore /
  • Poster
  • / Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.

Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.

Abstract Poster

Authors

null

Junning Cao

Fudan University Shanghai Cancer Center, Shanghai, China

Junning Cao , Pin Zhang , Paul L. de Souza , Bo Gao , Mark Voskoboynik , Dongmei Ji , Weina Shen , Sheng Yang , Yinglei Zhou , Rong Zhang , Jason D. Lickliter , Siao-Nge Hoon , David Palmieri , Suixiong Cai , Ye Edward Tian , Ning Ma , Cong Xu , Stone Yang , Shuaishuai Zhang , Binghe Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics and Tumor Biology (Nonimmuno)

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Conduct of Clinical Research

Clinical Trial Registration Number

NCT03508011 and NCT03507543

Citation

J Clin Oncol 37, 2019 (suppl; abstr 3059)

DOI

10.1200/JCO.2019.37.15_suppl.3059

Abstract #

3059

Poster Bd #

51

Abstract Disclosures

Similar Posters

First Author: Bo Gao

First Author: Ecaterina Elena Dumbrava

First Author: Seock-Ah Im

First Author: Andres Poveda